gemcitabine has been researched along with Atypical Lipomatous Tumor in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, JH; Baek, W; Han, YD; Jung, I; Kim, CG; Kim, HS; Kim, JE; Kim, JH; Kim, SH; Kim, SK; Koh, YW; Lee, YH; Rha, SY; Shin, SJ; Sim, NS; Yun, KH | 1 |
| Amini, B; Araujo, D; Benjamin, RS; Cloutier, JM; Conley, AP; Feig, B; Keung, EZ; Lin, H; Livingston, JA; Ludwig, J; Nassif, EF; Patel, S; Ratan, R; Ravi, V; Roland, CL; Somaiah, N; Thirasastr, P; Wang, WL; Zarzour, MA; Zhou, X | 1 |
| Blay, JY | 1 |
| Fukushima, T; Gomi, D; Hara, H; Kobayashi, T; Koizumi, T; Noguchi, T; Ozawa, T; Sekiguchi, N | 1 |
| Hirabayashi, K; Kikuta, K; Kondo, T; Noguchi, R; Ono, T; Ozawa, I; Sei, A; Yoshimatsu, Y | 1 |
| Awasthi, A; Bill, KLJ; Brock, GN; Bupathi, M; Chen, JL; Demoret, B; Duggan, MC; Hays, JL; Millis, SZ; Pollock, RE; Seligson, ND; Shakya, R; Stets, CW; Timmers, CD; Wakely, PE | 1 |
| Barangi, M; Bouvet, M; Chawla, SP; Endo, I; Higuchi, T; Hiroshima, Y; Hoffman, RM; Homma, Y; Katsuya, Y; Li, Y; Matsuyama, R; Miyake, K; Murakami, T; Nelson, SD; Oshiro, H; Park, JH; Razmjooei, S; Singh, SR; Sugisawa, N; Zhang, Z | 1 |
| Hohenberger, P; Kasper, B; Mathew, M; Pink, D; Rauch, G; Reichardt, P; Sommer, M | 1 |
| Bui-Nguyen, B; Italiano, A; Toulmonde, M | 1 |
| Ahler, E; Benz, MR; Braas, D; Christofk, HR; Eilber, FC; Nathanson, D; Riedinger, M; Smith, KB; Tam, B; Tap, WD; Witte, ON; Wu, H | 1 |
| Ayedi, L; Ayoub, A; Jlidi, R; Ketata, W; Msaad, S; Sellami, T; Yangui, I | 1 |
2 review(s) available for gemcitabine and Atypical Lipomatous Tumor
| Article | Year |
|---|---|
Giant paratesticular liposarcoma with lung metastases: a case report and review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Docetaxel; Fatal Outcome; Gemcitabine; Humans; Liposarcoma; Lung Neoplasms; Male; Orchiectomy; Testicular Neoplasms | 2020 |
[Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Docetaxel; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Leiomyosarcoma; Liposarcoma; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tetrahydroisoquinolines; Trabectedin | 2010 |
2 trial(s) available for gemcitabine and Atypical Lipomatous Tumor
| Article | Year |
|---|---|
Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma.
Topics: Deoxycytidine; Furans; Gemcitabine; Humans; Ketones; Leiomyosarcoma; Liposarcoma; Treatment Outcome | 2022 |
Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Deoxycytidine; Dioxoles; Drug Therapy, Combination; Female; Gemcitabine; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Sarcoma; Tetrahydroisoquinolines; Thrombocytopenia; Trabectedin; Transaminases | 2015 |
7 other study(ies) available for gemcitabine and Atypical Lipomatous Tumor
| Article | Year |
|---|---|
Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma.
Topics: Adult; Aged; Aged, 80 and over; Docetaxel; Gemcitabine; Humans; Liposarcoma; Middle Aged; Retrospective Studies; Trabectedin | 2023 |
Treatment of advanced soft tissue sarcoma by histological subtype: wish, prediction or reality?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Female; Furans; Gemcitabine; Humans; Ifosfamide; Indazoles; Ketones; Liposarcoma; Middle Aged; Prognosis; Pyrimidines; Sulfonamides; Survival Rate; Trabectedin | 2019 |
Establishment and characterization of NCC-PLPS1-C1, a novel patient-derived cell line of pleomorphic liposarcoma.
Topics: Antineoplastic Agents; Bortezomib; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Depsipeptides; Drug Screening Assays, Antitumor; Gemcitabine; Gene Deletion; Genes, Neoplasm; Humans; Liposarcoma; Male; Middle Aged; Neoplasm Invasiveness | 2021 |
Degree of
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Gene Amplification; Humans; Liposarcoma; Mice; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Proto-Oncogene Proteins c-mdm2; Retrospective Studies; Surgical Procedures, Operative; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Heterografts; Humans; Indazoles; Liposarcoma; Male; Mice; Mice, Nude; Neoplasm Recurrence, Local; Pyrimidines; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Chromatography, Liquid; Deoxycytidine; Female; Gemcitabine; Humans; Liposarcoma; Metabolomics; Mice; Tandem Mass Spectrometry; Xenograft Model Antitumor Assays | 2012 |
[A rare primary tumor of the mediastinum: pleomorphic liposarcoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chest Pain; Cisplatin; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Liposarcoma; Male; Mediastinal Neoplasms | 2007 |